文献速递流行病学与生物统计真实世界研究与卫生经济

SPRINT降压策略在中国人群的适用性与成本效果:建模研究

Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
PubMed 文献 · PLoS Med · 2021-03-04

采用微观模拟模型预测强化降压(SBP<120 mmHg)相较标准降压(SBP<140 mmHg)可减少心衰和心血管死亡并节约生命年,每获得1个QALY增量成本为国际元10,997,具有成本效果。

要点

  • 符合者中66.4%未接受高血压治疗,22.9%收缩压130-139 mmHg且未用药。

核心结论

  • 采用SPRINT强化降压策略虽增加需强化治疗人数,但可预防心血管事件、增加生命年并在常用阈值下具成本效果。

研究设计与样本

  • 基于CHARLS 2011-2012全国代表性基线数据估计符合SPRINT标准的人群规模。
  • 采用经验证的微观模拟模型预测强化与标准降压策略的成本、临床结局和QALY。

主要发现

  • 5年内强化治疗减少心衰0.84百万例(95%CI 0.42-1.25)、心血管死亡2.03百万例(95%CI 1.44-2.63),节约3.84百万生命年(95%CI 1.53-6.34)。
  • 心肌梗死减少0.069百万例(95%CI -0.28至0.42)和卒中减少0.36百万例(95%CI -0.10至0.82)无统计学意义。

关键数值与推荐

  • 终生强化治疗使平均QALY从9.51增至9.87,增量0.38(95%CI 0.13-0.71),每QALY增量成本国际元10,997。
  • 单因素敏感性分析最不利结果为高降压药成本(每QALY国际元25,291)和心血管死亡疗效较低(每QALY国际元18,995)。
  • 强化治疗低于支付阈值国际元16,782(2017年中国人均GDP 1倍)的概率为82.8%,收缩压130-139 mmHg人群为72.9%,女性为91.2%。

临床怎么用

  • 中国符合SPRINT标准人群庞大且多数未治疗,强化降压策略具成本效果潜力。
  • 收缩压130-139 mmHg未用药人群成本效果概率较低,需个体化评估。
  • 女性中强化降压成本效果概率较高,可优先考虑。

局限性

  • CHARLS调查缺乏SPRINT特异性纳入信息。
  • 不同血压测量技术的影响存在不确定性。
  • 数据来源多样且高度依赖SPRINT结果。
  • 严重不良事件率信息有限。
  • 缺乏药物对肾脏疾病疗效的信息和证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Systolic Blood Pressure Intervention Trial (SPRINT) showed significant reductions in death and cardiovascular disease (CVD) risk with a systolic blood pressure (SBP) goal of <120 mm Hg compared with a SBP goal of <140 mm Hg. Our study aimed to assess the applicability of SPRINT to Chinese adults. Additionally, we sought to predict the medical and economic implications of this intensive SBP treatment among those meeting SPRINT eligibility. METHODS AND FINDINGS: We used nationally representative baseline data from the China Health and Retirement Longitudinal Study (CHARLS) (2011-2012) to estimate the prevalence and number of Chinese adults aged 45 years and older who meet SPRINT criteria. A validated microsimulation model was employed to project costs, clinical outcomes, and quality-adjusted life-years (QALYs) among SPRINT-eligible adults, under 2 alternative treatment strategies (SBP goal of <120 mm Hg [intensive treatment] and SBP goal of <140 mm Hg [standard treatment]). Overall, 22.2% met the SPRINT criteria, representing 116.2 (95% CI 107.5 to 124.8) million people in China. Of these, 66.4%, representing 77.2 (95% CI 69.3 to 85.0) million, were not being treated for hypertension, and 22.9%, representing 26.6 (95% CI 22.4 to 30.7) million, had a SBP between 130 and 139 mm Hg, yet were not taking antihypertensive medication. We estimated that over 5 years, compared to standard treatment, intensive treatment would reduce heart failure incidence by 0.84 (95% CI 0.42 to 1.25) million cases, reduce CVD deaths by 2.03 (95% CI 1.44 to 2.63) million cases, and save 3.84 (95% CI 1.53 to 6.34) million life-years. Estimated reductions of 0.069 (95% CI -0.28, 0.42) million myocardial infarction cases and 0.36 (95% CI -0.10, 0.82) million stroke cases were not statistically significant. Furthermore, over a lifetime, moving from standard to intensive treatment increased the mean QALYs from 9.51 to 9.87 (an increment of 0.38 [95% CI 0.13 to 0.71]), at a cost of Int$10,997 per QALY gained. Of all 1-way sensitivity analyses, high antihypertensive drug cost and lower treatment efficacy for CVD death resulted in the 2 most unfavorable results (Int$25,291 and Int$18,995 per QALY were gained, respectively). Simulation results indicated that intensive treatment could be cost-effective (82.8% probability of being below the willingness-to-pay threshold of Int$16,782 [1× GDP per capita in China in 2017]), with a lower probability in people with SBP 130-139 mm Hg (72.9%) but a higher probability among females (91.2%). Main limitations include lack of specific SPRINT eligibility information in the CHARLS survey, uncertainty about the implications of different blood pressure measurement techniques, the use of several sources of data with large reliance on findings from SPPRINT, limited information about the serious adverse event rate, and lack of information and evidence for medication effectiveness on renal disease. CONCLUSIONS: Although adoption of the SPRINT treatment strategy would increase the number of Chinese adults requiring SBP treatment intensification, this approach has the potential to prevent CVD events, to produce gains in life-years, and to be cost-effective under common thresholds.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Li C, Chen K, Cornelius V, et al. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. PLoS Med. 2021. PMID: 33661907. doi:10.1371/journal.pmed.1003515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。